Another very good presentation from Steven.
Yes, much of what's presented we have seen...However the rewards are always in listening to Steven talk which often sheds greater light on what's been happening, equally what's coming.
The OmniCar presentation has taken a significant step in quality, there is a very nice intro and additional video/slides demonstrating the platforms capabilities.
There was an awesome slide with data demonstrating the recent in-vitro testing of OmniCAR’s ability to target individual cancer cell profiles...With 2 different cancer cells, they added one binder that only killed it's designed target and did not touch the second cancer profile...They then added the second binder and immediate simultaneous killing of both cancer cells commenced demonstrating complete targeting control...Very exciting.
PTX-100....Steven explained that there was a delay on manufacturing caused by compounding delays from supplier to supplier to supplier...However PTX has been bumped up the list with the drug now in it's manufacturing run and possibly on route...Steven is meeting with Professor Miles Prince (Head of Epworth Hematology and lead on PTX-100 trial) Friday who is ready to go with patient recruits.
Steven said that despite global market volatility, nothing has changed with the fundamentals of PTX. In fact Steven said that as of today we have never been in a stronger position actually.
I can almost bet the house we will see 'Merchant Funds' taking a placement, possibly any day now. Merchant Funds have now openly declared they have commenced building a position in PTX this month, precedent will show they don't do things by half measure & a large placement is extremely likely. Given the volume levels, I don't believe that Merchant Funds have taken a position via on market accumulation. A placement is just an educated prediction of mine, let's see how it plays out.
Let's say hypothetically it's a 50,000,000 placement at .17c that's $8.5m in the bank, in addition to our existing $15m and likely further $6m in option conversion by March 2023...That's a possible $30m in cash with $1.2m quarterly expenditure at current burn...Shares on issue would still be air tight...Yes it's a hypothetical picture in regards to any potential placement but you only have to look at Merchants participation levels in other declared positions.
Merchant also declared that their new stake in PTX was driven by OmniCar, looking to give their portfolio increased exposure to next generation cell therapies. This means to me that regardless of PTX-100 & PTX-200 data, Merchant stands to be a possible long term stable partner with a track record of raising funds for trials.
Steven was very open of Prescient’s willingness & capacity to collaborate with potential partners...He said if they have a cell program, let's make it better with our modular OmniCar system and put it in the cell bank/library to join our current 3 in-house programs...Mentioned that at every conference they attend, there has been a long line of big pharma waiting to talk to PTX about OmniCar.
I personally feel the next few months may be a turning point, Steven mentioned that he was waiting on patents to announce the Stealth mode program which is a possibility this month if the slide was any indication, Q1 I believe if things go well. You also throw in the fact that Merchant Funds have declared they have taken a position and are bullish on PTX...Let's see if Steven has an announcement regarding a placement any day now.
NASDAQ, DOW & S&P 500 are all flying overnight on a side note which may mean the ASX is in for another green day.
Expand
(20min delay)